



NOVEMBER 2024

## KMAP GENERAL BULLETIN 24225

# MAT Injectable Products Coverage Update

Effective with retroactive service dates to April 1, 2023, Brixadi (J0576) and future generics will be managed like other Medication-Assisted Treatment (MAT) drugs.

Brixadi will be covered under medical and pharmacy benefits. All Risk Evaluation and Mitigation Strategy (REMS) Program rules for this drug must be followed.

### **Original Policy Correction:**

#### Office Based Opioid Treatment (OBOT)

MAT drugs dispensed at the pharmacy and delivered to an OBOT provider are covered under Medicare Part D.

If an OBOT provider purchases a MAT product and administers it to the patient in the provider setting, this would be a physician-administered drug covered under Medicare Part B.

### **Original Policy Clarification:**

Billing codes G2068 and 80348 cannot be billed within the same 14 days **of each other**.

All other coverage criteria, coding guidelines, benefit limitations, and billing requirements will remain the same for MAT Opioid Treatment Programs (OTP) and OBOT programs.

**Note:** The effective date of the policy is April 1, 2023. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The **KanCare Open Claims Resolution Log** on the KMAP [Bulletins](#) page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.

#### **KMAP**

[Kansas Medical Assistance Program](#)

- [Bulletins](#)
- [Manuals](#)
- [Forms](#)

#### Customer Service

- 1-800-933-6593
- 7:30 a.m. - 5:30 p.m.  
Monday - Friday

For the changes resulting from this provider bulletin, view the updated *Mental Health Fee-for-Service Provider Manual*, Section 8400, pages 8-13, 8-15, 8-17, and 8-18.

Gainwell Technologies is the fiscal agent for KMAP